Pembrolizumab
Primary Mediastinal Large B-Cell Lymphoma
Explore 81 assets in Primary Mediastinal Large B-Cell Lymphoma →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Seda S. Tolu
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07283822CT.gov Amping up With PemJAK | — | Recruiting | — | — | — |
NCT06504394CT.gov A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | — | Active Not Recruiting | — | — | — |
NCT05934448CT.gov Pembro Plus CAR T-cell Therapy in R/R in PMBCL | — | Recruiting | — | — | — |
NCT05507541CT.gov TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04875195CT.gov A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | — | Completed | — | — | — |
NCT04187872CT.gov LITT and Pembrolizumab in Recurrent Brain Metastasis | — | Terminated | — | — | — |
NCT03210662CT.gov Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03035331CT.gov Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03150329CT.gov Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | — | Active Not Recruiting | — | — | — |
NCT02576990CT.gov Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT01953692CT.gov A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Mediastinal Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Seda S. Tolu | P2 | BB · 68 |
| Isocyclophosphamide | David Bond, MD | P4 | BBB |
| Adriamycin | University of Washington | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| (+)-Vincristine | Sun Yat-sen University | P4 | BBB |
| Axicabtagene Ciloleucel | AIDS Malignancy Consortium | P2 | BB |
| Vincristine Sulfate | National Research Center for Hematology, Russia | P3 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P4 | BB |
| Prednisone | University of Washington | P3 | BB |
+42 more in the Primary Mediastinal Large B-Cell Lymphoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Primary Mediastinal Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-primary-mediastinal-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →